Patients in whom treatment was discontinued · patients with Guillain‐Barré syndrome
IVIg leads to lower participants in whom treatment was discontinued compared with PE (high certainty).
1 finding from 1 review
Number of patients with adverse events attributed to treatment · patients with Guillain‐Barré syndrome
IVIg showed no clear difference in number of participants with adverse events attributed to treatment compared with PE (moderate certainty).
1 finding from 1 review
Anti‐endotoxin E5 versus placebo, all‐ cause mortality · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies showed no clear difference in anti‐endotoxin E5 versus placebo, all‐ cause mortality compared with placebo (moderate certainty).
1 finding from 1 review
Anti‐endotoxin ‐ HA‐1A versus placebo, all‐cause mortality · patients with sepsis, severe sepsis, septic shock
It is very uncertain whether monoclonal antibodies changes anti‐endotoxin ‐ HA‐1A versus placebo, all‐cause mortality compared with placebo (very low certainty).
3 findings from 1 review
RR 0.8 [0.54, 1.2]
3 studies · 2668 participants
Very low
RR 1.01 [0.94, 1.09]
6 studies · 4443 participants
Moderate
RR 0.92 [0.79, 1.06]
8 studies · 4676 participants
Low
Anti‐endotoxins Anti‐LPS versus placebo, all‐cause mortality · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies showed no clear difference in anti‐endotoxins Anti‐LPS versus placebo, all‐cause mortality compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality ‐ sensitivity analysis · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies showed no clear difference in anti‐endotoxin, all‐cause mortality ‐ low risk of bias studies compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality a. Intervention vs metformin [a. 24 weeks to 4 years] b. Intervention vs thiazolidinediones [b. 24 weeks to 4 years] c. Intervention vs insulin [c. 9 months to 10 years] d. Intervention vs incretin‐based control [d. 52 weeks to... · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies showed no clear difference in anti‐endotoxin, all‐cause mortality ‐ unclear risk of bias compared with placebo (moderate certainty).
1 finding from 1 review
Anti‐cytokine, all‐cause mortality ‐ uncertain risk of bias · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies probably leads to lower anti‐cytokines versus placebo, all‐cause mortality compared with placebo (moderate certainty).
3 findings from 1 review
RR 0.92 [0.86, 0.97]
9 studies · 7893 participants
Moderate
RR 0.91 [0.86, 0.97]
7 studies · 7752 participants
Moderate
RR 0.89 [0.8, 1]
4 studies · 2687 participants
Moderate
Anticytokine ‐ anti‐TNF‐alpha versus placebo, all‐cause mortality · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies probably leads to lower anticytokine ‐ anti‐TNF‐alpha versus placebo, all‐cause mortality compared with placebo (moderate certainty).
1 finding from 1 review
Anti‐cytokines ‐ human interleukin‐1receptor antagonist versus placebo, all‐cause mortality · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies showed no clear difference in anti‐cytokines ‐ human interleukin‐1receptor antagonist versus… compared with placebo (moderate certainty).
1 finding from 1 review
Anti‐cytokine, all‐cause mortality ‐ low risk of bias studies · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies leads to lower anti‐cytokine, all‐cause mortality ‐ low risk of bias studies compared with placebo (high certainty).
1 finding from 1 review